Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 20, 2026

Target Corp (TGT) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic ...

View original at finance.yahoo.com
Target Corp (TGT) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic ... This article first appeared on GuruFocus. Net Sales: $25.4 billion, a 6.7% increase from last year…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Capital expenditures were approximately $1 billion in Q1 with full-year expectation of about $5 billion

    60% confidence
  • Dividend payments were $516 million in Q1, with a 1.8% increase in per share dividend

    60% confidence
  • Net Promoter Scores and satisfaction metrics reached three-year highs following new guest experience initiatives

    60% confidence
  • Growth was broad-based across both stores and digital channels, with notable increases in all six core merchandise categories

    60% confidence
  • Adjusted EPS of $1.71 was 32% higher than prior year adjusted EPS

    60% confidence
  • SG&A expenses increased due to higher investments in payroll, training, and marketing

    60% confidence
  • Broader operating environment remains uncertain with potential headwinds from consumer sentiment and economic conditions

    60% confidence
  • Target Plus achieved nearly 60% growth in first quarter GMV

    60% confidence
  • 7 new stores opened in Q1 including the 2,000th location, with plans to open more than 30 this year

    60% confidence
  • Net sales were $25.4 billion, a 6.7% increase from last year

    60% confidence
  • Digital channel first-party sales grew nearly 9%, with same-day delivery increasing by more than 27%

    60% confidence
  • Company is executing a multiyear strategy to revamp merchandising and store operations including new leadership roles

    60% confidence
  • Company expects more challenging prior-year comparisons and potential cost headwinds in the first half of the year

    60% confidence
  • SG&A expense rate of 21.9% was more than 2 percentage points higher than last year's rate of 19.3%

    60% confidence
  • Comparable sales grew 5.6%, driven by a 4.4% increase in traffic

    60% confidence
  • Gross margin rate was 29%, an improvement of 80 basis points from the previous year

    60% confidence
  • Categories like home and apparel have sales still below 2024 levels, indicating areas that need further improvement

    60% confidence
  • Operating margin rate of 4.5% was 80 basis points higher than last year's adjusted rate of 3.7%

    60% confidence

Data points we hold from this source

Target Corporation · total store count2000 stores
Target Corporation · same day delivery growth27 percent
Target Corporation · traffic growth4.4 percent
Target Corporation · sga rate21.9 percent
Target Corporation · operating margin4.5 percent
Target Corporation · operating margin prior year adjusted3.7 percent
Target Corporation · margin29.0 percent
Target Corporation · new stores opened7 stores
Target Corporation · gross margin yoy change0.80 percent
Target Corporation · sga rate prior year19.3 percent
Target Corporation · digital first party sales growth9 percent
Target Corporation · dividend payment516 USD
Target Corporation · capex1.0 USD
Target Corporation · comparable sales growth5.6 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com
Target Corp (TGT) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic ... — Source | Via News | ViaNews Market